Vir Biotechnology, Inc. has announced a significant collaboration with Gilead Sciences, Inc. to discover and develop novel T-cell engagers (TCEs) targeting solid tumors. This partnership is expected to enhance Vir's oncology portfolio while leveraging Gilead's development and commercialization expertise.
On October 14, 2026, Vir Biotechnology filed an 8-K report detailing the collaboration and a concurrent stock purchase agreement (SPA) with Gilead. The SPA indicates that Gilead will purchase 1,765,486 shares of Vir's common stock at a price of $14.16 per share, totaling approximately $25 million. This investment is subject to customary closing conditions.
The collaboration focuses on developing three novel PRO-XTEN dual-masked T-cell engager candidates, which are designed to target selected solid tumor-associated antigens. This innovative approach combines Vir's T-cell engager discovery and AI-enabled protein engineering capabilities with Gilead's oncology expertise.
Vir Biotechnology, based in San Francisco, operates within the biological products sector, specifically focusing on products that do not include diagnostic substances. The company is listed on the Nasdaq under the ticker symbol VIR and is classified as a large accelerated filer.
According to the filing, the collaboration is expected to generate multiple differentiated candidates aimed at addressing challenging solid tumors, which have high unmet medical needs. Marianne De Backer, President and CEO of Vir Biotechnology, expressed optimism about the collaboration, stating, "This transaction provides further external validation of Vir Biotechnology's integrated discovery capabilities and the broad potential of the PRO-XTEN platform."
In addition to the collaboration, the SPA includes standstill, voting, and lockup provisions that will last for one year after the anticipated closing date. After this period, Gilead may have the right to require Vir to register the resale of the shares purchased under specific circumstances.
This strategic partnership not only strengthens Vir's position in the oncology market but also reflects a growing trend in the biological products industry where companies are increasingly collaborating to innovate and develop new therapies. The collaboration with Gilead is particularly noteworthy as it represents a significant investment in Vir's future, potentially enhancing its research and development capabilities.
Details regarding the anticipated timeline for the collaboration and the SPA were not disclosed in the filing. However, the partnership is expected to advance both companies' oncology portfolios and contribute to the ongoing evolution of cancer treatment methodologies.
As this collaboration unfolds, it will be crucial to monitor the progress of the T-cell engagers and their potential impact on the treatment of solid tumors. The filing does not specify what happens next, but stakeholders will be keenly observing the developments arising from this partnership.